These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25766596)

  • 1. Targeting FcRn for the modulation of antibody dynamics.
    Ward ES; Devanaboyina SC; Ober RJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):131-41. PubMed ID: 25766596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.
    Ward ES; Ober RJ
    Adv Immunol; 2009; 103():77-115. PubMed ID: 19755184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
    Sockolosky JT; Szoka FC
    Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
    Challa DK; Velmurugan R; Ober RJ; Sally Ward E
    Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FcRn to Generate Antibody-Based Therapeutics.
    Ward ES; Ober RJ
    Trends Pharmacol Sci; 2018 Oct; 39(10):892-904. PubMed ID: 30143244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunologic functions of the neonatal Fc receptor for IgG.
    Rath T; Kuo TT; Baker K; Qiao SW; Kobayashi K; Yoshida M; Roopenian D; Fiebiger E; Lencer WI; Blumberg RS
    J Clin Immunol; 2013 Jan; 33 Suppl 1(Suppl 1):S9-17. PubMed ID: 22948741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple roles for the major histocompatibility complex class I- related receptor FcRn.
    Ghetie V; Ward ES
    Annu Rev Immunol; 2000; 18():739-66. PubMed ID: 10837074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
    Vaccaro C; Bawdon R; Wanjie S; Ober RJ; Ward ES
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18709-14. PubMed ID: 17116867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies directed against human FcRn and their applications.
    Christianson GJ; Sun VZ; Akilesh S; Pesavento E; Proetzel G; Roopenian DC
    MAbs; 2012; 4(2):208-16. PubMed ID: 22453095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the FcRn:IgG protein-protein interaction.
    Low SC; Mezo AR
    AAPS J; 2009 Sep; 11(3):432-4. PubMed ID: 19499344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.
    Ober RJ; Martinez C; Vaccaro C; Zhou J; Ward ES
    J Immunol; 2004 Feb; 172(4):2021-9. PubMed ID: 14764666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.